Maze Therapeutics is a clinical-stage biopharmaceutical company that uses human genetics and its Compass platform to develop novel small-molecule precision medicines for renal, cardiovascular and related metabolic diseases. Its pipeline is led by two wholly owned lead programs, MZE829 (an oral APOL1 inhibitor) and MZE782 (an oral SCL6A19 inhibitor). MZE829 is being evaluated for APOL1 kidney disease, including focal segmental glomerulosclerosis (FSGS), with a Phase 2 trial expected to begin by Q1 2025. MZE782 is in a Phase 1 healthy volunteer trial with plans to evaluate it for chronic kidney disease (CKD) and phenylketonuria (PKU); Phase 1 data are expected in the second half of 2025. The company announced an oversubscribed $115 million Series D financing (which included conversion of issued convertible notes previously purchased by existing investors) to support advancement of these clinical programs and future pipeline work. Maze is based in South San Francisco, Calif., and intends to use the financing to optimize its upcoming Phase 2 trial and further explore the potential of both lead programs. Maze Therapeutics applies advanced data science, human genetics and functional genomics via its Maze Compass platform to discover small-molecule and biologic therapies for genetically defined disorders. The company has generated nine programs and two joint ventures since its 2019 launch and is advancing programs across rare and common genetically defined diseases. Its most advanced programs include MZE001 for Pompe disease, an APOL1 program for chronic kidney disease, and an ATXN2 program for amyotrophic lateral sclerosis (ALS). MZE001 is expected to enter the clinic in the first half of 2022 as the company transitions to clinical-stage development. Maze intends to use its platform and the recent financing to expand variant functionalization and accelerate end-to-end computational chemistry–informed drug discovery. The company is based in South San Francisco. Maze Therapeutics was launched to translate human genetic insights—specifically genetic modifiers—into novel therapeutics. The company aims to expand understanding of natural disease protection provided by genetic modifiers by combining global studies of human genetic variation with large-scale gene perturbation experiments. Maze plans to use those integrated insights to create medicines built around protective modifier genes to treat multiple diseases. The company announced an initial investment commitment of $191 million to support its launch and R&D activities. Maze has assembled a team of prominent scientific founders and senior leaders to drive discovery and drug development.

Total raised

$496M

Funding rounds

3

Latest round

Series D

Latest activity

Dec 2024